PT2847335T - Alvejamento mediado por nuclease com vetores de alvejamento grandes - Google Patents
Alvejamento mediado por nuclease com vetores de alvejamento grandesInfo
- Publication number
- PT2847335T PT2847335T PT137207189T PT13720718T PT2847335T PT 2847335 T PT2847335 T PT 2847335T PT 137207189 T PT137207189 T PT 137207189T PT 13720718 T PT13720718 T PT 13720718T PT 2847335 T PT2847335 T PT 2847335T
- Authority
- PT
- Portugal
- Prior art keywords
- targeting
- nuclease
- mediated
- vectors
- targeting vectors
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title 2
- 101710163270 Nuclease Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638267P | 2012-04-25 | 2012-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2847335T true PT2847335T (pt) | 2018-09-28 |
Family
ID=48289700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137207189T PT2847335T (pt) | 2012-04-25 | 2013-04-25 | Alvejamento mediado por nuclease com vetores de alvejamento grandes |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9834786B2 (https=) |
| EP (1) | EP2847335B1 (https=) |
| JP (1) | JP6275120B2 (https=) |
| KR (1) | KR101904508B1 (https=) |
| CN (2) | CN104364380B (https=) |
| AU (1) | AU2013251558B2 (https=) |
| BR (1) | BR112014026294B1 (https=) |
| CA (1) | CA2869016C (https=) |
| CY (1) | CY1120572T1 (https=) |
| DK (1) | DK2847335T3 (https=) |
| ES (1) | ES2683071T3 (https=) |
| IL (1) | IL234905B (https=) |
| IN (1) | IN2014DN09261A (https=) |
| MX (1) | MX362523B (https=) |
| PL (1) | PL2847335T3 (https=) |
| PT (1) | PT2847335T (https=) |
| RU (1) | RU2645475C2 (https=) |
| SG (2) | SG11201406547YA (https=) |
| WO (1) | WO2013163394A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201406547YA (en) | 2012-04-25 | 2014-11-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| MX384291B (es) | 2013-02-20 | 2025-03-14 | Regeneron Pharma | Modificación genética de ratas. |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| EP3988649B1 (en) * | 2013-09-18 | 2024-11-27 | Kymab Limited | Methods, cells and organisms |
| KR101566498B1 (ko) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | 인터루킨 2 수용체 감마 유전자 적중벡터, 그 벡터가 도입된 면역세포 결핍 형질전환 미니 복제돼지 생산과 그 제조방법 및 활용 |
| US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| EP3080279B1 (en) | 2013-12-11 | 2018-09-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| KR102170502B1 (ko) * | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| HRP20200529T1 (hr) | 2014-06-06 | 2020-09-04 | Regeneron Pharmaceuticals, Inc. | Postupci i pripravci za modificiranje ciljnog lokusa |
| SI3161128T1 (sl) | 2014-06-26 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe |
| BR112017007770A2 (pt) | 2014-10-15 | 2018-01-16 | Regeneron Pharma | cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc. |
| KR102531016B1 (ko) | 2014-11-21 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
| ES2947714T3 (es) * | 2014-12-19 | 2023-08-17 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso |
| AU2016233250C1 (en) | 2015-03-16 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
| AU2016270587B2 (en) | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| CN109862785B (zh) | 2016-09-30 | 2022-09-06 | 瑞泽恩制药公司 | C9orf72基因座中具有六核苷酸重复扩增的非人类动物 |
| ES2996886T3 (en) | 2017-06-27 | 2025-02-13 | Regeneron Pharma | Rodents comprising a humanized asgr1 locus |
| CN110891420B (zh) | 2017-07-31 | 2022-06-03 | 瑞泽恩制药公司 | Cas转基因小鼠胚胎干细胞和小鼠及其应用 |
| KR20200033259A (ko) | 2017-07-31 | 2020-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물 |
| EP3585161A1 (en) | 2017-07-31 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
| US20190098879A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
| JP7097440B2 (ja) | 2017-11-10 | 2022-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｓｌｃ３０ａ８変異を含む非ヒト動物および使用方法 |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| JP7222075B2 (ja) | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
| KR102925054B1 (ko) | 2018-12-20 | 2026-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 뉴클레아제-매개 반복부 팽창 |
| KR102661779B1 (ko) | 2019-04-04 | 2024-04-30 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| RU2722933C1 (ru) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
| US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| WO2021263146A2 (en) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| KR20230152124A (ko) | 2021-03-05 | 2023-11-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 생체내 dna 조립 및 분석 |
| IL312505A (en) | 2021-11-04 | 2024-07-01 | Regeneron Pharma | Non-human animals comprising a modified cacng1 locus |
| KR20240117571A (ko) | 2021-12-08 | 2024-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 돌연변이 마이오실린 질환 모델 및 이의 용도 |
| US20250049006A1 (en) | 2021-12-20 | 2025-02-13 | C/O Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| AU2023218391A1 (en) | 2022-02-11 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
| IL317261A (en) | 2022-07-29 | 2025-01-01 | Regeneron Pharma | Non-human animals containing a modified transferrin receptor locus |
| JP2025525745A (ja) | 2022-08-05 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｄｐ－４３の凝集耐性バリアント |
| EP4593590A1 (en) | 2022-09-29 | 2025-08-06 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| AU2024214456A1 (en) | 2023-02-01 | 2025-07-03 | Regeneron Pharmaceuticals, Inc. | Animals comprising a modified klhdc7b locus |
| WO2024189098A1 (en) | 2023-03-13 | 2024-09-19 | Iomx Therapeutics Ag | Platform technology for the identification of modulators of immune effector cell function |
| WO2025122754A1 (en) | 2023-12-07 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Gaa knockout non-human animals |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| AU737155B2 (en) | 1997-03-14 | 2001-08-09 | Biogen Idec Inc. | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| WO2000039316A1 (en) | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
| CA2361191A1 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| AU776576B2 (en) * | 1999-12-06 | 2004-09-16 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| EP1587545A2 (en) * | 2003-01-13 | 2005-10-26 | Mahendra S. Rao | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| AU2004263865B2 (en) * | 2003-08-08 | 2007-05-17 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| DE602008003684D1 (de) | 2007-04-26 | 2011-01-05 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
| PL2602323T3 (pl) | 2007-06-01 | 2018-06-29 | Open Monoclonal Technology, Inc. | Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego |
| SG191561A1 (en) | 2008-08-22 | 2013-07-31 | Sangamo Biosciences Inc | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP2180058A1 (en) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuclease recombination system |
| EP2352369B1 (en) | 2008-12-04 | 2017-04-26 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| WO2010124200A2 (en) | 2009-04-23 | 2010-10-28 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cancer |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| EP2456876A2 (en) | 2009-07-24 | 2012-05-30 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cytokine-cytokine signaling pathways |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| EP2493288B1 (en) * | 2009-10-28 | 2015-02-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
| CA2779858C (en) | 2009-10-29 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Multifunctional alleles |
| WO2011053957A2 (en) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions and methods for the regulation of multiple genes of interest in a cell |
| EP2508595B1 (en) | 2009-12-01 | 2016-11-23 | National Cancer Center | Method for constructing chimeric rat using rat embryonic stem cells |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| CN102791865B (zh) | 2009-12-21 | 2015-07-01 | 凯津公司 | 用于转染原生质体的改进技术 |
| PH12012501467B1 (en) | 2010-01-22 | 2018-07-04 | Corteva Agriscience Llc | Excision of transgenes in genetically modified organisms |
| EP2660318A1 (en) * | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| MY191870A (en) | 2010-06-11 | 2022-07-18 | Regeneron Pharma | Production of fertile xy female animals from xy es cells |
| AU2011281062B2 (en) * | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| WO2012168307A2 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| CN107858333B (zh) | 2011-10-28 | 2022-05-27 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| SG11201406547YA (en) | 2012-04-25 | 2014-11-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
| AU2013259647B2 (en) | 2012-05-07 | 2018-11-08 | Corteva Agriscience Llc | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| CN104540382A (zh) | 2012-06-12 | 2015-04-22 | 弗·哈夫曼-拉罗切有限公司 | 用于产生条件性敲除等位基因的方法和组合物 |
| AU2013293270B2 (en) | 2012-07-25 | 2018-08-16 | Massachusetts Institute Of Technology | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
| AU2013335451C1 (en) | 2012-10-23 | 2024-07-04 | Toolgen Incorporated | Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3031921B1 (en) | 2012-12-12 | 2025-03-12 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| ES2953523T3 (es) | 2012-12-27 | 2023-11-14 | Keygene Nv | Método para inducir una translocación dirigida en una planta |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| MX384291B (es) | 2013-02-20 | 2025-03-14 | Regeneron Pharma | Modificación genética de ratas. |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| EP2922393B2 (en) | 2013-02-27 | 2022-12-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
| WO2014143381A1 (en) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events |
| RU2662932C2 (ru) | 2013-03-14 | 2018-07-31 | Карибо Биосайенсиз, Инк. | Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| EP4286517A3 (en) | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| US20160186208A1 (en) | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
| US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
| US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
| KR102170502B1 (ko) | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| HRP20200529T1 (hr) | 2014-06-06 | 2020-09-04 | Regeneron Pharmaceuticals, Inc. | Postupci i pripravci za modificiranje ciljnog lokusa |
| SI3161128T1 (sl) | 2014-06-26 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| ES2947714T3 (es) | 2014-12-19 | 2023-08-17 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso |
-
2013
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 BR BR112014026294-2A patent/BR112014026294B1/pt active IP Right Grant
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 CA CA2869016A patent/CA2869016C/en active Active
- 2013-04-25 MX MX2014012994A patent/MX362523B/es active IP Right Grant
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
- 2013-04-25 PL PL13720718T patent/PL2847335T3/pl unknown
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/en not_active Ceased
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/es active Active
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/zh active Active
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/zh active Active
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/ko active Active
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/ru active
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/en active Active
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/ja active Active
- 2013-04-25 PT PT137207189T patent/PT2847335T/pt unknown
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201702445TA (en) | Nuclease-mediated targeting with large targeting vectors | |
| IL236563A (en) | Target a search-driven connection | |
| GB201217807D0 (en) | Location-assisted beamforming | |
| PL2713471T3 (pl) | Ładowarka | |
| AU347859S (en) | Battery | |
| AU346864S (en) | Battery | |
| ZA201500911B (en) | Enzymes | |
| EP2874517A4 (en) | SEAT LIFTING ARRANGEMENT | |
| GB201420527D0 (en) | Electrical-wire-protecting member | |
| GB2506566B (en) | Pole piece | |
| PL2815136T3 (pl) | Układ montażowy | |
| GB201212340D0 (en) | Antennas | |
| EP2905847A4 (en) | TOGETHER | |
| GB201213117D0 (en) | Transgene expression | |
| EP2865582A4 (en) | PRFV ELEMENT | |
| GB201214720D0 (en) | Maser assembly | |
| EP2914323A4 (en) | INTUMASK ARRANGEMENT | |
| GB201206455D0 (en) | Gene expression | |
| GB2518076B (en) | Electrical-wire-protecting member | |
| GB2501778B (en) | Power | |
| EP2939294A4 (en) | DRUMS | |
| GB201220119D0 (en) | Vector | |
| GB201207018D0 (en) | Enzymes | |
| GB201205795D0 (en) | Vector | |
| GB2507515B (en) | An assembly |